Fasting News and Research

RSS

First placebo-controlled clinical study results of BYETTA injection with Lantus presented at ADA 2010

Amylin Pharmaceuticals, Inc. and Eli Lilly and Company today announced results from the first double-blind, placebo-controlled clinical study to evaluate BYETTA (exenatide) injection added to Lantus (insulin glargine), which showed patients with type 2 diabetes achieved glucose targets without weight gain or increasing their risk of hypoglycemia. These findings were presented at the 70th Annual Scientific Sessions of the American Diabetes Association in Orlando, Fla.

28 Jun 2010

Linagliptin mono- and combination therapy improves blood glucose control

Linagliptin phase III data were presented for the first time this week at the 70th Scientific Sessions of the American Diabetes Association (ADA), showing that this investigational compound, a dipeptidyl peptidase (DPP)-4 inhibitor, achieved significant, sustained and clinically meaningful reductions in blood glucose as measured by haemoglobin A1c (HbA1c), fasting plasma glucose (FPG), and postprandial glucose (PPG) concentrations.(1-6) Linagliptin is being investigated by Boehringer Ingelheim as a once-daily oral treatment in type 2 diabetes.

28 Jun 2010

Arena's lorcaserin reduces body weight across patient subgroups

Arena Pharmaceuticals, Inc. today reported pooled Week 52 data from more than 6,000 patients in lorcaserin's pivotal Phase 3 clinical trial program that demonstrate lorcaserin 10 mg dosed twice daily reduced body weight in all patient subgroups evaluated, as defined by gender, age, ethnicity and starting body weight and Body Mass Index (BMI). Greater improvements in cardiovascular risk factors were also achieved with lorcaserin treatment compared to placebo overall and in most subgroups.

28 Jun 2010

In-school education programs can reduce obesity, other risk factors for type 2 diabetes: HEALTHY

Healthier cafeteria choices, longer and more intense periods of physical activity and robust in-school education programs can lower rates of obesity and other risk factors for type 2 diabetes, according to a national study called HEALTHY.

28 Jun 2010

Lantus and Apidra injections improve glycemic control, reduce hospital complications: Study

Sanofi-aventis announced today that results from the RAndomized Study of Basal Bolus Insulin Therapy in the Inpatient Management of Patients with Type 2 Diabetes Undergoing General Surgery (RABBIT-2 Surgery) found that treatment with a basal-bolus regimen that included Lantus (insulin glargine [rDNA origin] injection) once-daily and Apidra (insulin glulisine [rDNA origin] injection) before meals improved glycemic control and reduced hospital complications, compared to "sliding scale" insulin in general surgery patients with type 2 diabetes.

28 Jun 2010

Phase III clinical trials: Linagliptin achieves significant, sustained reductions in blood sugar

Data from four pivotal Phase III clinical trials demonstrate that linagliptin achieved statistically significant and sustained reductions in blood sugar as measured by hemoglobin A1c, fasting plasma glucose and postprandial glucose. Boehringer Ingelheim Pharmaceuticals, Inc. is investigating the dipeptidyl peptidase 4 inhibitor as an oral once-daily tablet, as monotherapy and combination therapy, to treat type 2 diabetes.

28 Jun 2010

Data on MetAP2 inhibitors for treatment of obesity presented at ADA 2010

Zafgen, Inc., a pharmaceutical company pioneering novel obesity therapeutics to help the body regain and sustain a lean, healthy state by targeting imbalances in fat metabolism, today announced data on ZGN-201, a prototype methionine aminopeptidase 2 inhibitor, for the treatment of obesity. Preclinical studies demonstrate MetAP2 inhibition eliminates excess body weight through the regulation of fat metabolism and food intake, and normalizes glucose tolerance in animal models.

28 Jun 2010

New preclinical data of XOMA 052 in animal model of Type 2 diabetes to be presented at ADA 2010

XOMA Ltd., a leader in the discovery and development of therapeutic antibodies, will be presenting new preclinical data in an animal model of Type 2 diabetes in which its anti-inflammatory therapeutic antibody candidate, XOMA 052, was used as monotherapy and in combination with the marketed anti-diabetic drugs exendin-4 (Byetta) or sitagliptin (Januvia).

28 Jun 2010

Data shows Victoza produces greater reductions in A1c, body weight and FPG than Januvia

Late-breaking Novo Nordisk extension data presented today at the 70th Annual Scientific Sessions of the American Diabetes Association showed that once-daily Victoza in combination with metformin produced sustained and significantly greater reductions in A1c, body weight and fasting plasma glucose than Januvia plus metformin at 52 weeks.

28 Jun 2010

Dapagliflozin as monotherapy demonstrates potential for type 2 diabetes treatment

Findings from a 24-week Phase 3 clinical study published online in the latest issue of Diabetes Care demonstrated that the investigational drug dapagliflozin, administered as a monotherapy, achieved statistically significant mean reductions at 5 mg and 10 mg doses once daily in the primary endpoint of glycosylated hemoglobin levels (HbA1c) in treatment-naïve adult patients with newly diagnosed type 2 diabetes, compared to placebo.

23 Jun 2010

Weight gain after age of 50 is associated with increased risk of diabetes after 65 years

For individuals 65 years of age and older, obesity, excess body fat around the waist and gaining weight after the age of 50 are associated with an increased risk of diabetes, according to a study in the June 23/30 issue of JAMA.

23 Jun 2010

Hunger hormone ghrelin heightens the appeal of high-calorie foods over low-calorie foods: Study

The "hunger" hormone ghrelin, which acts in the brain to stimulate hunger and increase food intake, heightens the appeal of high-calorie foods over low-calorie foods, according to a study that will be presented Tuesday at The Endocrine Society's 92nd Annual Meeting in San Diego.

22 Jun 2010

Obese women with insulin resistance lose more weight on lower-carbohydrate diet: Study

Obese women with insulin resistance lose more weight after three months on a lower-carbohydrate diet than on a traditional low-fat diet with the same number of calories, according to a new study. The results will be presented Saturday at The Endocrine Society's 92nd Annual Meeting in San Diego.

21 Jun 2010

Studies explore effects of fructose consumption on metabolic parameters in humans

New research released today from Rippe Lifestyle Institute and the University of Central Florida shows no difference between table sugar and high fructose corn syrup on weight gain or any changes in risk factors for metabolic syndrome or insulin resistance, a precursor to diabetes. Abstracts for the two studies are the first to provide longer term prospective data exploring the effects the normal consumption of fructose has on metabolic parameters in humans.

21 Jun 2010

AFREZZA non-inferior to standard therapy insulin lispro in reducing HbA1c levels of Type 1 diabetics

MannKind Corporation today announced that results of a new 16-week trial show that the investigational ultra rapid acting mealtime insulin, AFREZZA™ (insulin human [rDNA origin]) Inhalation Powder, combined with basal insulin, is clearly non-inferior to standard therapy insulin lispro, a rapid acting insulin, also combined with basal insulin, in reducing HbA1c levels in subjects with inadequately controlled Type 1 diabetes.

11 Jun 2010

Mutations in ion channels cause rare inherited pain disorder: Research

A mutation that enhances the function of a specific ion channel has been identified as the cause of a rare inherited pain disorder. The research, published by Cell Press in the June 10 issue of the journal Neuron, proposes a potential treatment for the disorder and may lead to a better understanding of chronic pain in humans.

10 Jun 2010

Value-based wellness programs for patients with metabolic syndrome

HealthInsight, provider of the leading health incentive platform, today announced a new addition to its value-based wellness programs for patients with metabolic syndrome. The program is designed to detect and manage the syndrome's symptoms before the condition becomes chronic, thereby allowing individuals to take preventive action and manage their overall health while reducing on-going treatment costs.

8 Jun 2010

Study identifies potential link between Gilbert's Syndrome, childhood acute lymphoblastic leukemia

Scientists from the Barbara Ann Karmanos Cancer Institute and Wayne State University School of Medicine, both in Detroit, and the Children's Hospital of Michigan/Detroit Medical Center, presented preliminary data that identified a potential link between Gilbert's Syndrome and the development of a specific subtype of childhood acute lymphoblastic leukemia (ALL). The findings were announced today at the 2010 American Society of Clinical Oncology Annual Meeting.

7 Jun 2010

Researchers find a way to isolate pancreatic islet cells from brain dead donors using DI

A team of researchers from several collaborating Baylor University research centers and from Japan's Okayama Graduate School of Medicine have found a way to more consistently isolate pancreatic islet cells from brain dead donors using ductal injection, a process that immediately cools donor islet cells at the injection site.

4 Jun 2010

Researchers analyze impact of health promotion program on cardiovascular disease-related medical, hospital costs

A comprehensive health promotion program reduced cardiovascular disease-related medical and hospital costs, according to a new study. CSX Transportation, a national company with 30,000 employees, developed the program in 2004 to address employees' high rates of cardiovascular disease when compared to national benchmarks and the associated higher healthcare costs.

21 May 2010

Fasting News and Research

First placebo-controlled clinical study results of BYETTA injection with Lantus presented at ADA 2010

Linagliptin mono- and combination therapy improves blood glucose control

Arena's lorcaserin reduces body weight across patient subgroups

In-school education programs can reduce obesity, other risk factors for type 2 diabetes: HEALTHY

Lantus and Apidra injections improve glycemic control, reduce hospital complications: Study

Phase III clinical trials: Linagliptin achieves significant, sustained reductions in blood sugar

Data on MetAP2 inhibitors for treatment of obesity presented at ADA 2010

New preclinical data of XOMA 052 in animal model of Type 2 diabetes to be presented at ADA 2010

Data shows Victoza produces greater reductions in A1c, body weight and FPG than Januvia

Dapagliflozin as monotherapy demonstrates potential for type 2 diabetes treatment

Weight gain after age of 50 is associated with increased risk of diabetes after 65 years

Hunger hormone ghrelin heightens the appeal of high-calorie foods over low-calorie foods: Study

Obese women with insulin resistance lose more weight on lower-carbohydrate diet: Study

Studies explore effects of fructose consumption on metabolic parameters in humans

AFREZZA non-inferior to standard therapy insulin lispro in reducing HbA1c levels of Type 1 diabetics

Mutations in ion channels cause rare inherited pain disorder: Research

Value-based wellness programs for patients with metabolic syndrome

Study identifies potential link between Gilbert's Syndrome, childhood acute lymphoblastic leukemia

Researchers find a way to isolate pancreatic islet cells from brain dead donors using DI

Researchers analyze impact of health promotion program on cardiovascular disease-related medical, hospital costs

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News